The most comprehensive tumor test to determine HRD status in patients with ovarian cancer1
The first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status
This FDA-approved test helps provide information on the magnitude of benefit for PARP inhibitor therapy
Fact Sheets and Product Info:
Find more Myriad info as well as links to National Institutes of Health cancer resources.
- myChoice CDx Physician Resources
- myChoice CDx Patient Education
- MedlinePlus – Health Topics: Ovarian Cancer
- National Cancer Institute: Genetics – BRCA Gene Mutations: Cancer Risk and Genetic Testing
- National Cancer Institute: Cancer Treatment – Types of Cancer Treatment: Targeted Therapy to Treat Cancer
About myChoice CDx:
Myriad myChoice® CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.
The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes, or may become eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes or a positive Genomic Instability Score, for treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling.
See intended use statement for complete details.